Optogenetic Bioproduction Platform

About Ningaloo Biosystems

Ningaloo Biosystems is a Munich-based biotech startup founded in 2020, developing a novel optogenetic platform for industrial bioproduction. Their core technology uses light to precisely control gene expression and cellular activity in production cell lines like CHO and HEK, enabling dynamic, tunable manufacturing of complex biologics. This approach seeks to address key bottlenecks in biopharma manufacturing—cost, scalability, and product quality—with the goal of making next-generation therapies more affordable and widely available. The company is in the platform development and validation stage, collaborating with academic partners and generating proof-of-concept data for applications like bispecific antibody production.